Non-critically ill hospitalized patients with newly diagnosed hyperglycemia or type 2 diabetes, a subcutaneous basal-bolus insulin regimen in combination with a correction insulin scale is safe to administer according to the 2012 Endocrine Society clinical practice guideline [75] (Table 4). Here, INS is linked to Hyperglycemia.